Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326149116/en/
Investors:
Caroline Corner
[email protected]
415-202-5678
Media:
[email protected]
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- THine Announces New VCSEL Drivers and TIAs for Ultra-Low-Latency, Lower-Power, High-Density, and Cost-Effective Scale-Up Networks to Enable Next-Generation Large-Scale AI Datacenters
- Supremo Announces Availability of Shopify Inventory Management App Following June 2026 Launch
- Domo Announces Timing for Second Quarter Fiscal 2027 Financial Results and Provides Transaction Timing Update
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share